Transforming life for people living with Parkinson’s and other CNS disorders

Transforming life for people living with Parkinson’s and other CNS disorders

LATEST PRESS RELEASES
OCTOBER 3, 2024

Positive data from the first part of IRLAB’s Phase I study with the drug candidate IRL757

Gothenburg, Sweden, October 3 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) – a company discovering and developing novel treatments for Parkinson’s disease – today announces that the company has successfully completed the first part of its Phase I clinical trial with single ascending doses (SAD) of the drug candidate IRL757, which is being developed for the treatment of apathy. The results show that IRL757 is well absorbed, provides good exposure in the body and has a good tolerability and safety profile. IRLAB has recently secured full funding for the project through clinical proof-of-concept studies.

Read More >

Watch IRLAB’s
Capital Markets Day 2023!

IRLAB A
12.95
SEK
TODAY
0.00 %
TODAY SEK
0.00 SEK
12:19:05
2024-10-04
More share info >

ISP – The proprietary technology platform

IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

IRLAB’s clinical phase II candidates

Mesdopetam (IRL790)

In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.  

Pirepemat (IRL752)

In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.

LATEST PRESENTATION
SEPTEMBER 17, 2024

Q&A with Kristina Torfgård, CEO, at “Investing in Life Science 2024”

Kristina Torfgård, CEO, interviewed at “Investing in Life Science 2024”, an event hosted by BioStock and VatorSecurities, held on September 12, 2024. In Swedish only.

Read More >